Bayer has jettisoned one of the two immune checkpoint regulators it picked up from Compugen. The decision follows a review that foresaw bleak prospects for the program and little reason to invest in its development.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.